SPINEGUARD : Jack Shuang HouInstitute of Chemistry, Chinese Academy of Sciences ICCAS

SPO9147

26 janv. 2026 •18:16

🦴⚡️ Omnia Medical Launches FDA-Cleared #PsiF DNA™ System — A New Minimally Invasive Option for SI Joint Fusion

Big commercialization milestone in spine + interventional pain: Omnia Medical announced the commercial launch of its FDA-cleared #PsiF DNA™ Sacroiliac Joint Stabilization System, following FDA 510(k) clearance and a successful physician-feedback “alpha launch.”

Why this matters

👇

🏥 1️⃣ SI joint pain is real—and solutions must be predictable + minimally invasive
The #PsiF DNA™ System is intended for sacroiliac joint fusion, including degenerative sacroiliitis and SI joint disruptions, and was engineered for a minimally invasive posterior approach—a workflow many pain/spine specialists prefer for procedural efficiency.


🧬 2️⃣ Smart fixation concept: designed to reduce migration risk
The implant trajectory goes ilium → across SI joint → into sacrum, designed to enhance fixation by engaging both sides of the joint and lowering migration risk.


🌀 3️⃣ Differentiator: “double-helix” architecture + autograft biology
A standout feature is the double-helix design, leveraging autograft bone from both the ilium and sacrum to support arthrodesis and long-term stabilization—combining mechanical stability + biological fusion support.


🧭 4️⃣ Guidance tech built-in: @PsiF Guard™ for real-time intraoperative feedback
@PsiF Guard™ (developed through a partnership with @SpineGuard) provides real-time intraoperative feedback to support accurate placement and confirmation—exactly the kind of “confidence layer” that drives adoption in minimally invasive procedures

.

🗣️ Key voices to highlight

@Abigail Mann — Project Manager, SI Technologies, @Omnia Medical: emphasized physician-driven tech that supports procedural consistency.
Troy Schifano — Chief Executive Officer, @Omnia Medical: highlighted fusion biology + efficiency by using autograft from both sides of the joint.


📍 Commercial momentum
Omnia Medical will formally introduce @PsiF DNA™ at the North American Neuromodulation Society Annual Meeting in Las Vegas on Jan 23, 2026 (Booth #639).


💡 My takeaway
In SI joint fusion, the winners are usually the systems that deliver repeatable placement, strong fixation, and fusion-friendly biology—without adding workflow burden. #PsiF DNA™ is positioning itself right in that sweet spot: posterior MIS design + migration-conscious fixation + biologic fusion logic + intraoperative guidance support.